pyrroles has been researched along with Hematologic Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, S; Carpio, C; Cassier, PA; Chatterjee, M; Chromik, J; de Vos, F; DeAngelo, DJ; Esteve, J; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Kiladjian, JJ; Lin, CC; Mariconti, L; Meille, C; Minami, H; Mous, R; Pereira, B; Radhakrishnan, R; Steeghs, N; Stein, EM; Suarez, C; Tai, D; Yamamoto, N | 1 |
| Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G | 1 |
| Bai, R; Biagioni, S; Cavallini, C; Coluccia, A; Coluccia, AML; Da Pozzo, E; Hamel, E; La Regina, G; Liu, T; Martini, C; Mazzoccoli, C; Mazzoni, C; Nalli, M; Orlando, V; Puxeddu, M; Shen, H; Silvestri, R | 1 |
| Abdel-Wahab, O; Abramson, D; Arcila, ME; Berger, MF; Ceyhan-Birsoy, O; De Munck, S; Decaux, O; Diamond, EL; Drilon, A; Dunkel, IJ; Durham, BH; Emile, JF; Erickson, C; Geissmann, F; Haroche, J; Hyman, DM; Ki, M; Lacouture, ME; Ladanyi, M; Lopez Rodrigo, E; Lu, SX; Mandelker, D; Mora, J; Pannecoucke, E; Pastore, A; Petrova-Drus, K; Picarsic, J; Rotemberg, V; Saganty, R; Santa-María López, V; Savvides, SN; Solit, DB; Ulaner, GA; Walsh, M; Yabe, M; Yoshimi, A | 1 |
| Ashelford, K; Corcoran, DB; Fegan, CD; Giles, PJ; Lewis, T; Miraz Rahman, K; Pepper, AGS; Pepper, C; Thurston, DE; Walsby, EJ | 1 |
| Bochner, BS; Kuang, FL; Kudlaty, E; Perez, M; Stein, BL | 1 |
| Andrews, KL; Booker, SK; Canon, J; Cee, VJ; Chavez, F; Chen, Y; Eastwood, H; Guerrero, N; Herberich, B; Hickman, D; Lanman, BA; Laszlo, J; Lee, MR; Lipford, JR; Mattson, B; Mohr, C; Nguyen, Y; Norman, MH; Pettus, LH; Powers, D; Reed, AB; Rex, K; Sastri, C; Tamayo, N; Tasker, AS; Wang, HL; Wang, P; Winston, JT; Wu, B; Wu, Q; Wu, T; Wurz, RP; Xu, Y; Zhou, Y | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Li, Z; Liang, F; Liu, Y; Shen, X; Sheng, H; Song, T; Xue, Z; Zhang, Z; Zhao, Y | 1 |
| Brundage, KM; Bunner, P; Craig, MD; Cumpston, A; Gibson, LF; Hamadani, M; Petros, W; Remick, SC; Tse, W; Vos, JA; Wen, S | 1 |
| Anderson, MA; Huang, D; Roberts, A | 1 |
| Amin, S; Claxton, D; Doi, K; Dower, C; Gowda, K; Lin, JM; Liu, Q; Loughran, TP; Sung, SS; Wang, HG | 1 |
| Akarca, AU; Barry, C; Britten, CE; D'Hooge, F; Flynn, MJ; Hartley, JA; Havenith, CE; Howard, PW; Janghra, N; Levy, JN; Marafioti, T; Masterson, LA; Parren, PW; Tiberghien, A; Tyrer, PC; van Berkel, PH; Williams, DG; Zammarchi, F | 1 |
| Bane, FT; Bannon, JH; Campaini, G; Campiani, G; Mc Gee, MM; Pennington, SR; Williams, DC; Zisterer, DM | 1 |
| Boggon, TJ; Cornejo, MG; Mercher, T | 1 |
| Dobre, S; Fewkes, NM; Guimond, M; Krauss, AC; Mackall, CL; Meadors, JL | 1 |
| Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C | 1 |
| Huang, DC; Khaw, SL; Roberts, AW | 1 |
| Anderson, KC; Podar, K | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; García-Echeverría, C; Hideshima, T; Hofmann, F; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Pearson, MA; Poulaki, V; Shringarpure, R | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Taguchi, H; Tasaka, T; Togitani, K; Yang, Y | 1 |
| Grosicka, A; Grosicki, S; Hołowiecki, J | 1 |
| Giles, FJ | 1 |
6 review(s) available for pyrroles and Hematologic Neoplasms
| Article | Year |
|---|---|
Targeting BCL2 for the treatment of lymphoid malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Gossypol; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2014 |
JAK3: a two-faced player in hematological disorders.
Topics: Animals; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Interleukin Receptor Common gamma Subunit; Janus Kinase 3; Lymphocytes; Mice; Piperidines; Pyrimidines; Pyrroles; Receptors, Cytokine; Signal Transduction | 2009 |
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Hematologic Neoplasms; Humans; Indoles; Molecular Mimicry; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2007 |
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Disease Progression; Endothelial Growth Factors; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Indoles; Lymphokines; Matrix Metalloproteinases; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
3 trial(s) available for pyrroles and Hematologic Neoplasms
| Article | Year |
|---|---|
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Topics: Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Neoplasms; Pyrimidines; Pyrroles; Tumor Suppressor Protein p53 | 2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles | 2022 |
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Topics: Administration, Oral; Adult; Aged; Atorvastatin; Bacterial Infections; Cytokines; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Siblings; Survival Analysis; Tissue Donors; Transplantation Immunology; Transplantation, Homologous; Treatment Outcome; Virus Diseases; Young Adult | 2013 |
14 other study(ies) available for pyrroles and Hematologic Neoplasms
| Article | Year |
|---|---|
Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Glioblastoma; Hematologic Neoplasms; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Molecular Structure; Optical Imaging; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Topics: Adolescent; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Benzothiazoles; Child; Child, Preschool; Exome Sequencing; Female; Genome, Human; Hematologic Neoplasms; Histiocytosis; Humans; Infant; Male; Mutation; Picolinic Acids; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Twins, Monozygotic; Young Adult | 2019 |
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Piperidines; Pyrroles; Tumor Microenvironment | 2021 |
Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.
Topics: Anaphylaxis; Hematologic Neoplasms; Humans; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Pyrazoles; Pyrroles; Triazines; Tryptases | 2021 |
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.
Topics: Animals; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Mice, SCID; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyrroles; Quinazolinones; Structure-Activity Relationship; Swine; Xenograft Model Antitumor Assays | 2019 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1.
Topics: Acenaphthenes; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Hematologic Neoplasms; Humans; Lethal Dose 50; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2013 |
Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Hematologic Neoplasms; Humans; Models, Molecular; Molecular Conformation; Myeloid Cell Leukemia Sequence 1 Protein; Phenols; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Pyrroles; Stromal Cells; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodiazepines; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hematologic Neoplasms; Histones; Humans; Immunoconjugates; Interleukin-2 Receptor alpha Subunit; Mice; Pyrroles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1,
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Division; Cell Membrane; Cell Nucleus; Cyclophilin A; Cytoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; G2 Phase; Hematologic Neoplasms; Humans; Hydrolysis; Microtubules; Monocytes; NIMA-Interacting Peptidylprolyl Isomerase; Oxazepines; Paclitaxel; Peptide Mapping; Peptidylprolyl Isomerase; Pyrroles; Silver Staining; Trypsin | 2009 |
Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow; Flow Cytometry; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Homeodomain Proteins; Immunoprecipitation; Indoles; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Thymus Gland | 2010 |
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib | 2011 |
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Topics: Antineoplastic Agents; Bone Marrow; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Hematologic Neoplasms; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Everolimus; Hematologic Neoplasms; Humans; Indoles; Leukemia; Mutation; Phosphoproteins; Protein Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2006 |